Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-4365359 ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - Purchase, NY – August 8, 2024 – Cognition The ...

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...

Cognition Therapeutics (NASDAQ:CGTX) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 'SHINE' study. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. More Monday Stock Market News What's Next for CGTX Stock Thi ...

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - "The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements ...

Core Insights - Cognition Therapeutics, Inc. reported positive results from the Phase 2 'SHINE' study of CT1812, showing cognitive improvement in participants treated for six months compared to placebo across various cognitive measures [1][9][12] - The study demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events being mild or moderate [10][12][18] - CT1812 showed significant changes in neurofilament light chain, a marker of neurodegeneration, particularly at the 300mg dose [2][12] Study Details - The SHINE study enrolled 153 adults with mild-to-moderate Alzheimer's disease, randomized to receive either placebo or one of two doses of CT1812 (100mg or 300mg) [18][22] - The primary endpoint was safety and tolerability, while the key secondary endpoint focused on cognitive measures, specifically ADAS-Cog 11 [22] - Participants in the placebo arm experienced a decline of approximately 2.70 points on ADAS-Cog 11, while those treated with CT1812 declined by an average of 1.66 points, indicating a 39% slowing of decline [18][22] Clinical Implications - The results suggest that CT1812 may serve as a monotherapy or in combination with approved drugs for treating Alzheimer's disease and related dementias [9][12] - The findings from the SHINE study will inform future clinical trials and dose selection for CT1812 [9][12][12] - The company is also conducting additional studies, including the SHIMMER trial for Lewy body dementia and the START trial for early-stage Alzheimer's disease [11][23] Safety Profile - The overall percentage of participants experiencing any adverse event was similar between CT1812 treatment arms (76.5%) and the placebo group (78%) [10][12] - Serious adverse events were reported in 6% of CT1812-treated participants compared to 10% in the placebo group [19] - Treatment-emergent liver function test (LFT) increases were observed in the 300mg group but subsided after drug cessation without serious liver injury [3][10] Future Outlook - The company is optimistic about the SHINE results and anticipates further insights from ongoing trials [11][12] - Cognition Therapeutics has received over $170 million in grant support from various institutions, aiding its research and development efforts [11] - The company aims to advance CT1812 in clinical trials targeting neurodegenerative diseases, leveraging the distinct mechanism of action of the σ-2 receptor [24]

The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant ...

Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday. AAIC Presentation details 1. Abstract #95147: CSF Phosphoproteomics Biomarker An ...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, ...